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Platelet-activating factor (PAF)' is a phospholipid (1-0-alkyl-2-sn-acetyl-glycero-
3-phosphocholine) mediator of inflammation and endotoxic shock (1) . Polymor-
phonuclear neutrophils(PMN), peritoneal macrophages, vascular endothelial cells,
basophils, and platelets synthesize PAF rapidly after appropriate stimuli (1) . For ex-
ample, TNFor phagocytosis promotesynthesis and release ofPAF inPMN or mac-
rophages within 10 min (2) . These stimuli induce phospholipase A2 (PLA2) activity
that cleavesmembrane phospholipids into lyso-PAF and arachidonic acid, andacetyl-
CoA:lyso-PAF acetyltransferase that producesPAFby acetylatinglyso-PAE Thrombin
stimulates PAFsynthesis in endothelial cells also within 10 min (3) . Otherproteinases,
such as elastase, stimulate PAF synthesis rapidly in PMN, macrophages, and en-
dothelial cells (4), and induce PLA2 and acetyltransferase activity (5) . Conversely,
different proteinase inhibitors block PAF synthesis induced by TNF (2, 4) . These
findings led to thehypothesis that proteinases added to cells andcellular proteinases
activated by TNF cleave proteins inhibitory for PLA2, such as lipocortins (4) .
Lipocortins belong to a family of related proteins that mediate theantiinflamma-
tory activity of corticosteroids (6) . Lipocortins inhibit PLA2 activity in vitro by a
mechanism still unclear (7-8) . Furthermore, recombinant lipocortin I inhibits ei-
cosanoid synthesis in vivo in perfused lungs(9). Cloning and sequencing oflipocortins
cDNA has provided the aminoacid sequence ofthese proteins (10-12) . Another steroid-
induced protein with PLA2 inhibitory activity is uteroglobin, a rabbit secretory pro-
tein (13) . Two identical subunits of 70 aminoacids form uteroglobin (14) ; lipocortin
I and II comprise four nonidentical repeats of 70 amino acids (see reference 15 for
review). Miele et al. (15) have noticed a striking sequence similarity between amino
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acid residues 40-46 of uteroglobin and 247-253 of lipocortin I, repeat 3. Synthetic
peptides designated "antiflammins" that correspond to such sequences show potent
PLA2 inhibitory activity in vitro and an antiinflammatory effect on carrageenan-
induced rat foot pad edema in vivo (15).
In this paper we examine whether antiflammins inhibit synthesis of a phospho-
lipid mediator of inflammation, such as PAF, in intact cells. These peptides inhibit
PAF synthesis in PMN, macrophages, and endothelial cellsstimulatedby TNF, phago-
cytosis, or proteinases. The antiflammins inhibit also PMN aggregation and
chemotaxis, and suppress the inflammatory reaction induced in rat skin by in situ
formation of immune complexes or by intradermal injection of TNF and comple-
ment component C5a.
Materials and Methods
Materials.
￿
Human rTNF was a gift of the Suntory Institute for Biomedical Research, Osaka,
Japan. Peptides MQMKKVLDS (antiflammin-1) and WKLFKKIEKV (a synthetic peptide
corresponding to residues 2 to 11 of cecropin, a moth polypeptide) were a gift of Dr. Anil
B. Mukherjee ofthe National Institutes ofHealth (Bethesda, MD). Peptide HDMNKVLDL
(antiflammin-2) was purchased from Peptide Biotechnologies (Washington, DC). These pep-
tides were stored under nitrogen in sealed glass vials and dissolved in Tris buffer, pH 8, con-
taining 10 mM 0-mercaptoethanol (ME) or 1 mM dithiothreitol to prepare 0.1 MM stock
solutions that were kept at 2°C and diluted before each assay. Control incubations received
the same amount ofME or dithiothreitol. Opsonized yeast spores (BYS-C3b) were prepared
as described (4). The PAF receptor antagonist SRI 63072 was obtained from Sandoz (East
Hanover, NJ).
Cell Preparation and PAF Assay.
￿
Human PMN were prepraed as described (4) and
resuspended at 5 x 106/ml in Tris-buffered Tyrode's containing 0.25% delipidated BSA (T-f-
BSA) with calcium and magnesium. Rat peritoneal macrophages and human vascular en-
dothelial cells were prepared and cultured as described (2). In standard assays, 2.5 x 106
PMN or 106 rat peritoneal macrophages were incubated at 37°C in 0.5 ml reactions with
rTNF, 20 pl of BYS-C3b suspension (ti10 spores/cell), and other additions indicated in the
text. Endothelial cells were grown in multiwell plates (N5 x 106 cells/35 mm well) and treated
in 1 ml of Iscove's medium containing 0.25% BSA. PAF released into the medium or as-
sociated with cells was isolated, characterized, and measured as described (2).
Enzymatic Assays.
￿
The preparation ofcell homogenate and the assay conditions for acetyl-
CoA:lyso-PAF acetyltransferase have been described in detail (16). This enzymatic activity
is expressed in nanomoles of [3H]acetate incorporated into PAF per minute of incubation
and milligram of cell homogenate protein (16). PLA2 activity was measured in PMN
homogenates according to Blackwell et al. (17), with minor modifications. The reactions con-
tained 0.1 ml of PMN sonicate (30-6014g of protein) and 500 nM a'-palmitoyl, ,Q-1-['4C]oleyl,
La-phosphatidylcholine (400 nCi) dispersed in 0.9 ml of 0.5 M Tris buffer, pH 8, and 50
mM CaCl2. After l h at 37°C, 2 ml of methanol and 2 ml of chloroform were added. The
samples were extracted and the chloroform phase was separated and dried. The product of
hydrolysis, [14C]oleic acid, was separated from unhydrolyzed substrate by TLC on silica gel
using chloroform/methanol/acetic acid (70:10 :1) as solvent. Unhydrolyzed phosphatide and
oleic acid were eluted to measure percent hydrolysis. This enzymatic activity is expressed
per microgram ofPMN protein. The release oflabel from PMN preincubated with [' 4C]ar-
achidonic acid was assayed according to Hirata et al. (18). 101 PMN in 5 ml of modified Gey's
solution were incubated with 1 .25 /Ci ["C]arachidonic acid at 37°C for 45 min, washed
twice, and resuspended in this solution; 50% of the label was incorporated by PMN. The
release of label was measured by centrifuging the cells and counting the supernatant.
Preparation ofHuman C5a.
￿
Human C5a was prepared according to Vallota and Muller-
Eberhard (19). Briefly, normal human serum was incubated with yeast spores afterinhibition
of the anaphylatoxin inactivator with e-aminocaproic acid (19). The C5a was purified by threeCAMUSSI ET AL.
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sequential chromatographies on CM-cellulose, Sephadex G100, and CM-Sephadex C50; the
biologic activity of C5a was assayed by testing its contractile property on guinea pig ileum
(19). The minimal effective concentration was 2.5 x 10-1° M. C5a-des-Arg was prepared by
digestion with carboxypeptidase B, as described (20).
Neutrophil Aggregation and Chemotaxis. PMN aggregation was measured following a
modification (21) ofthe methodofCraddock et al. (22). The PMN were resuspended at 1.5 x
106/ml in TTBSA containing 1.5 mM Ca" and Mg2` ; 0.45 ml of this suspension were in-
cubated in a silicone-coated cuvette ofan aggregometer (Elvi 840, Milan, Italy). After 2 min
at 37°C, 50 1l ofC5a-des-Arg preparation were added. The resulting changes in lighttrans-
mission were recorded as AT. Chemotaxis assays were carried out in Boyden chambers ac-
cording to Venge (23). 1 .5 x 106 PMN in 0.5 ml of TTBSA were placed in the upper
chamber that was separated from the bottom one by a Millipore filter of3-,Um pore size and
150-/Am thickness. The bottom chamber contained TTBSA with or without 0.2 wg/ml ofC5a.
After a 75-min incubation at 37°C, the upper chamber was emptied and washed with PBS
containing 2 mM EDTA to remove the cells that had not entered into the filters. To quantitate
Chmotaxis, the filters were removed, washed in PBS, and stained with 0.2% crystal violet
in 1017o ethanol. The filters were thoroughlywashed with water and the dye was eluted with
33% acetic acid to measure the Asno.
Arthus Reaction and Intradermal Injection of C5a or TNF .
￿
20 mg of BSA and 25 mg of Evans
blue in 0.5 m1 of PBS were injected intravenously in female Lewis rats (130-150 g) per 100
g body weight. After 30 min, we injected intradermally 80 Ag of purified rabbit anti-BSA
antibody in 0.1 ml of PBS to induce an Arthus reaction (24). In control experiments, we
injected 80 tzg ofnonimmune rabbit Ig. An injection of Evans blue alone was followed after
30 min by intradermal injection of either 50 jig C5a or 0.2 tzg rTNF in 0.1 ml PBS. We in-
jected PBS alone in control experiments. Antiflammin-2 or a control peptide were injected
intradermally. The PAF receptor antagonist SRI 63072 was injected intraperitoneally (2 .5
mg/100 g body weight). The rats were killed after 3 h and the area of blueing was first mea-
sured. Skin discs -2.5 cm in diameter were then excised, fixed in 10° Jo formalin, pH 7.2,
embedded in paraffin, and processed for light microscopy examination. PMN present around
venulae and arterioles in the deep layer of dermis were counted in an area of 690 x 46 p,m
in the center of the site of intradermal injections. The results are expressed as PMN per
0.032 mm2.
Results
Antiammins Inhibit PAF Synthesis.
￿
The peptide HDMNKVLDL (AF2) corre-
sponding to residues 246-254 of lipocortin I (12) inhibited PAF synthesis induced
by rTNF in macrophages with an IC5o of -100 nM (Fig. 1). The peptide
MQMKKVLDS (AF1) corresponding to region 39-47 ofuteroglobin (13) was much
less inhibitory for PAF synthesis than AF-2 (Fig. 1). The peptide WKLFKKIEKV
was used as a control since it is similar in size to antiflammins but it is not inhibitory
for PLA2 (Mukherjee, A. B., personal communication). This peptide had no effect
on PAF synthesis (data not shown).
To establish whether antiflammins are inhibitory in different cell types and for
different species, we examined the effect of AF-2 on PAF synthesis also in human
PMN and endothelial cells. At 100 nM concentration, this peptide inhibited PAF
synthesis N80% in rTNFtreated PMN and -60% in PMN stimulated by phagocy-
tosis or elastase (Table 1). It should be pointed out that elastase did not inactivate
AF-2, since its inhibitory activity did not decrease after a 30-min incubation with
1 FAg/ml of this proteinase. PAF synthesis was also inhibited by 100 nM AF-2 in en-
dothelial cellsstimulated by thrombin (Table II) and in rat macrophages stimulated
by phagocytosis (data not shown). Incubation with AF-2 had no effect on cell via-
bility, since >95% ofthe endothelial cells and >90% of PMN stimulated by various916
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FIGURE 1. Antiflammins in-
hibitPAF synthesis induced by
rTNF in rat peritoneal macro-
phages.Thesecells were prein-
cubatedfor30 minat 22°Cwith
theconcentration ofAF-1 or AF-
2shownin theabscissa andthen
stimulated with 20 ng/ml of
rTNF for 10 min at 37°C. (A)
PAFreleased into themedium;
(B) PAF cell-associated. The
mean t SD of three experi-
ments is reported.
treatments excludedtrypan blue. Therefore, AF-2inhibited PAFsynthesisin different
cells stimulated by a variety ofagents without apparent toxicity.
The inhibition ofPAF synthesis byAF-2 was reversible when this peptide was re-
movedbywashing thecells. PMN and macrophages preincubated with 100 nM AF
2, washed and then stimulated byrTNForphagocytosis, synthesizedPAFin amounts
comparable to control cells (Table III). These cells were preincubated withoutAF-2
and washed in the same way, since this treatment was found to reduce somewhat
PAF synthesisin response todifferent stimuli. Theseresults showthat thecontinuous
presence ofAF-2 is required to inhibit PAF synthesis.
Inactivation ofAntiammins.
￿
In the experiments described above, weused 0.1 mM
stock solutionsofantiflammins dissolved in buffer containing 10mM MEor 1 mM
dithiothreitol. These reducingagents were addedto protect methionineresiduesfrom
oxidation and were present in incubations with different cells at concentrations up
to 50 wM. Control experiments were carried out with PMN incubated in medium
containing 0.1-1 mM ME, but no inhibition of PAF synthesis was detected (dataCAMUSSI ET AL.
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TABLE I
Antiammin-2 Inhibits PAF Synthesis and Acetyl-CoA:lyso-PAF
Acetyltransferase Activity Induced by Different Stimuli in Human Neutrophils
Antiflammin-2 was added for 30 min to PMN kept at 22°C; control PMN were
preincubated without additions. PMN were stimulated with 10 ng/ml of rTNF
or 1 kg/ml of elastase for 10 min, and with BYS-C3b for 20 min at 37°C . PAF
released from 2 x 106 PMN and cell-associated was measured as described in
Materials and Methods . Cell homogenates were prepared to assay the acetyl-
CoA:lyso-PAF acetyltransferase activity (expressed in nmol lyso-PAF acetylated/
min/mg of protein. The mean t SD of PAF and acetyltransferase values ob-
tained in three experiments are shown .
not shown). This finding indicated that ME alone had no effect on PAF synthesis.
However, the antiflammins lost their inhibitory activity when the reducing agents
were omitted from the incubations or stock solutions of peptides were frozen. We
have no explanation for the loss of activity of antiflammins upon freezing, but we
routinely kept antiflammin stock solutions at 2°C.
Experiments with PMN showed that AF-1 did not inhibit PAF synthesis after a
30 min preincubation at 22°C; such preincubationhad little effect on the inhibitory
activity of AF-2 (Fig. 2). In these experiments, PMN were stimulated by rTNF or
phagocytosis after an increasing preincubation with antiflammins. Without prein-
cubation, 500 nM AF-1 partially inhibited PAF synthesis; after 5 min preincuba-
tion, it was no longer inhibitory (Fig. 2). These results suggest that AF-1 is inacti-
TABLE II
Antiflammin-2 Inhibits PAF Synthesis and Acetyl-CoA :lyso-PAF
Acetyltransferase Activity Induced by Thrombin in Human Endothelial Cells
Endothelial cells were treated with AF-2 as described in Table I and stimulated
with 0.2 U/ml ofthrombin for 30 min. The mean t SD ofPAF and acetyltrans-
ferase values determined in three experiments are shown.
Inducer Antiflammin-2
PAF
Released Cell-bound Acetyltransferase
nM ng/ml nmol/min/mg
None - 0.4 ± 0.2 0.4 t 0.3 0.5 t 0.1
rTNF - 6.2 t 1 .3 4.5 t 0.9 4.9 ± 1 .5
rTNF 100 1 .6 t 0.7 1 .1 t 0.9 1 .2 t 0.2
rTNF 50 3.5 1 0.9 2.8 ± 1 .2 1 .5 ± 0.2
BYS-C3b - 10.4±2.3 7.8±2.5 6.4± 1 .3
BYS-C3b 100 4.5 ± 0.8 2.1 ± 1 .1 1 .3 ± 0.2
BYS-C3b 50 6.3 ± 1 .1 5.9 t 1 .3 1 .8 ± 0.1
Elastase - 7 .4 t 1 .1 4.7 t 1 .2 3.8 ± 1 .2
Elastase 100 2.5 t 0.5 1 .9 ± 1 .3 0.9 ± 0.6
Antiflammin-2
nM
Cell-bound PAF
ng/ml
Acetyltransferase
nmol/min/mg
Untreated control 0.4 ± 0 .2 0.2 t 0.1
0 5.8 ± 1 .8 2.8 ± 0.9
100 3.7 t 0.8 1 .8 ± 0.3
500 0.3 ± 0.1 0.3 ± 0.2918
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TABLE III
Reversal of the Inhibitory Effect on PAF Synthesis by Washing
Neutrophils or Macrophages after a Pretreatment with Antiflammin-2
Cells Inducer
Neutrophils rTNF
rTNF
BYS-C3b
BYS.C3b
Macrophages
￿
BYS-C3b
￿
-
￿
5.2 t 1 .3
￿
3.1 t 1 .9
BYS-C3b
￿
100
￿
4.2 f 0.5
￿
3.9 t 1 .8
The cells were preincubated with or without AF-2 for 30 min at 22°C, washed
twice with TT-BSA, and treated with 10 ng/ml rTNF for 10 min or with BYS-C3b
for 20 min. PAY released into the culture medium or cell-associated was mea-
sured as described in Table I. The mean t SD values obtained in three experi-
ments are shown.
vated by PMN. Therefore, the stability ofdifferent antiflammins maybe important
for their inhibitory activity. Furthermore, AF-2 inhibited PAF synthesis without a
detectable lag.
Antiflammin-2 Inhibits Enzymatic Activities Inducedfor PAF Synthesis.
￿
According to
Miele et al. (15), antiflammins at a 50 nM concentration inhibit -90% ofisolated
porcine pancreatic PLA2 activity in an in vitro assay. To confirm these data in a
different system, we assayed the effect of antiflammins on PLA2 activity in PMN
homogenate. In this assay (see Materials and Methods), -85% ofthe substrate was
hydrolyzed in 1 h by homogenate ofuntreated PMN; 100 nM AF-2 inhibited this
hydrolysis -50%, whereas AF-1 was much less inhibitory (Table IV). It should be
pointed out that this assay did not measure a specific PLA2 activity but rather the
combined activity of different PMN phospholipases that can hydrolyse the labeled
substrate previously used by Blackwell et al. (17). Our results are in agreement with
min.
B
￿
FIGURE 2.
￿
The effect ofprein-
cubation with human neutro-
phils on the inhibitory activity
of antiflammins. PMN were
preincubated with 500 nM AF-1
(0)or 200 nM AF-2 (A) for the
time shown in the abscissa and
then stimulated with 10 ng/ml
ofrTNF (A) or by phagocytosis
ofyeast spores (B). PAF released
into the medium is reported to-
gether with values for control
cells incubated without anti-
flammins (/). Table I shows
control values for released PAF
-r--T-"f-r--
￿
ofunstimulated cells. The mean
0
￿
5
￿
30
￿
t SD of three experiments is
reported.
Antiflammin-2 Re eased
PAF
C ll-bound
nM ng/ml
- 3.1 t 1 .2 1 .5 t 1 .8
100 2.9 t 1 .1 1 .3 t 1 .1
- 8.2 t 1 .3 7.1 t 1 .9
100 7.8 t 1 .2 6.9 t 3.16-
4
q
2_
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TABLE IV
Antiflammins Inhibit Phos¢holipase A2 Activity in Neutrophils Homogenate
The PLA2 activity was measured in sonicated human PMN accordingto Black-
well et al. (17). The [14C]oleic acid hydrolyzed per microgram of protein is in-
dicated as a percent of the substrate input. The mean t SD values obtained
in three experiments are shown.
those reported by Miele et al. (15) with isolated PLA2, with the exception of the
low inhibitoryactivity ofAF1. This peptide is apparently lessactive than AF-2 both
in intact cells and in the crude cell-free system used in the present experiments.
To evaluate the effect ofantiflammins on PLA2 activity in intact cells, we labeled
PMN with [14Clarachidonic acid. The release oflabel in the supernatant was con-
sidered to reflect the cellular PLA2 activity. TNF or phagocytosis stimulated PMN
torelease 2.3- and 5.4-fold morelabelthan control cells, respectively; AF-2 inhibited
such release with an IC50 of -100 nM (Fig. 3 A). This IC50 is similar to that
reported above forthe inhibitionofPAF synthesis by AF-2, suggesting that this pep-
tide inhibits a phospholipase activity involved in both release oflabel from PMN
and synthesis of PAR
FIGURE 3.
￿
Antiflammin-2 inhibits thereleaseoflabelfrom PMN preincubated with [14Clara-
chidonicacid andstimulated by rTNF or phagocytosis. Human PMNwere firstlabeled andthen
stimulatedwith 10 ng/mlofrTNF or with baker'syeastspores (BYS-C3b), as describedin Materials
andMethods. TheAF-2 wasadded5minbefore stimulation. (A)Thelabelreleased in the super-
natant after20 min by 2.5 x 106 PMN is shown for untreated cells (/) and for rTNF (") or
BYS-C3b-treatedcells("). (B) Thekinetics oflabelreleasefrom 1.25 x 106 PMNis shown for
cells untreated(0) and stimulated by phagocytosis with (*) or without(T)200nM AF-2. The
experiments were carried out in triplicate and the SD (not shown) was <10%.
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Additions nM Hydrolysis Inhibition
%
None - 1.59 t 1.2 -
AF-1 100 1.34 t 0.3 16
AF-1 1,000 0.31 t 0.1 81
AF-2 10 1.71 t 0.6 0
AF-2 100 0.75 t 0.2 53
AF-2 200 0.41 t 0.1 74920
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The kinetics oflabel release was examined in PMN preincubated with ["C]ara-
chidonic acid and stimulated by phagocytosis (Fig. 3 B). Control cells released some
label in the first 5 min of incubation and relatively little afterwards; PMN stimu-
lated byphagocytosis released gradually up to 7% ofthe label incorporated during
the preincubation in 20 min (the last point examined). This release was drastically
inhibited by 200 nM AF-2 (Fig. 3 B).
The inhibition ofPLA2 activity by antiflammins may by itself account for their
effect on PAF synthesis. However, the acetyl-CoA:lyso-PAF acetyltransferase is also
induced in cells stimulated to produce PAF (1). It was therefore of interest to inves-
tigate the effect ofantiflammins on this enzymatic activity. AF-2 did not significantly
inhibit the acetyltransferase when added to homogenates prepared from PMN or
macrophages stimulated byrTNF or phagocytosis. As an example, the homogenate
ofPMN stimulated byphagocytosis acetylated 6.3 nmoloflyso-PAF/min/mg ofpro-
tein vs. 5.9 nmol in the presence of 100 nM AF-2. However, the activation of the
acetyltransferasewas inhibitedwhen thecellswere treatedwithAF-2 before stimulating
PAF synthesis. Homogenates of TNFtreated rat macrophages showed a -10-fold
increase in acetyltransferase activity over control cells; addition ofAF-2 to the cul-
turemedium inhibited this increase(Fig. 4). The acetyltransferase activity was8-12-
fold higher in homogenates ofhuman PMN stimulated by TNF, phagocytosis, or
elastase than in control untreated cells; 50 nM AF-2 inhibited this induction of
acetyltransferase activity ti75°Jo and 100 nM AF-2 inhibited >85% (Table I). We
observed a similar inhibition in endothelial cells stimulated by thrombin (Table II).
Therefore, AF-2 inhibited the activation ofacetyltransferaseat somewhat lowercon-
centrations than those inhibitory for PAF synthesis.
e
E
c
4"
31
nM
AF-1
AF-?
FIGURE 4.
￿
Antiflammins inhib-
it theacetyl-CoA:lyso-PAFace-
tyltransferase inducedby rTNF
in rat peritoneal macrophages.
These cells were preincubated
with AF-1 or AF-2 andthen stim-
ulated with rTNF, as indicated
in Fig. 1. Cell homogenates were
prepared andassayed foracetyl-
transferase activity. Themean
t SD of three experiments is
shown.CAMUSSI ET AL.
TABLE V
Effect of Lyso-PAF on the Inhibition of PAF Synthesis by Antflammin-2
or p-Bromo-Diphenacylbromide in Neutrophils Stimulated by Phagocytosis
A preincubation (10 min at 22°C) with AF-2 or 1 kM PBDB preceded the stimu-
lation with BYS-C3b (20 min at 37°C). Control samples were treated with BYS-
C3b only or with BYS-C3b and AF-2. Where indicated, we added 100 t.M lyso-
PAF during the incubation at 37°C . The antiflammin and PBDB were present
throughout this incubation. The mean t SD obtained in three experiments are
shown.
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This inhibition ofacetyltransferase activation is surprising, since AF-2 is suppos-
edly a specific PLA2 inhibitor (15). Experiments carried out with PMN provided
further evidence for this effect of AF-2 (Table V). Addition of the PLA2 product
lyso-PAF failed to promote PAF synthesis in PMN stimulated by phagocytosis but
treated with AF2. In contrast, lyso-PAF promoted PAF synthesis when the PLA2
activity was inhibited by p-bromo-diphenacylbromide (PBDB). These results sug-
gest that PBDB inhibits PLA2 but not the acetyltransferase, whereas AF-2 inhibits
both enzymatic activities. Such inhibitionis not explained by a requirement for in-
creased PLA2 activity to induce the acetyltransferase, since in PMN treated with
PBDB concentrations inhibitory for PLA2 (2) the acetyltransferae is activated. For
example, homogenates of control PMN acetylated 0.4 nmol of lyso-PAF/min/mg
protein; homogenates of PMN treated with 1 I.M PBDB and then stimulated by
TNF or phagocytosis acetylated 3.2 and 6.1 nmol of lyso-PAF, respectively.
Antiflammins InhibitAggregation and Chemotaxis ofNeutrophils.
￿
Stimuli that induce
PAF release by PMN, such as C5a-des-Arg (20), promote aggregation ofthese cells
(22, 25). To establish whether antiflammins inhibit this biological activity mediated
by PAF, we treated human PMN with C5a-des-Arg for 2 min. We measured PMN
aggregation by recordinglight transmission inacuvette (21); 100 nMAF-2 inhibited
completely PMN aggregation, but 100 nM AF-1 inhibited N60°Io (Fig. 5A). A con-
trol peptidedid not inhibitPMNaggregation (Fig. 5 A). ThePAFreceptor antagonist
SRI 63072 was N707o inhibitory at 5 jiM concentration (data not shown). These
results show that antiflammins are potent inhibitors ofa biological response medi-
ated by PAF production. AF-1 may be more active in this assay because ofthe rela-
tively short incubation time.
Weexaminednexttheeffect ofantiflammins onthestimulationofPMN chemotaxis
by C5a. This assay was performed in Boyden chambers containing 0.2 Wg/ml ofC5a
in the bottom compartment. The PMN migrating into the filter separating the two
chambers were measuredby stainingwith crystal violet (see Materials and Methods).
Additions Antiflammin-2
PAF
Released Cell-bound
nM ng/ml
Untreated - 0.4 t 0.2 0.3 t 0.2
Control - 10.2 t 2 .5 9.7 t 1 .7
Control 100 5.1 t 1 .3 3.2 t 1,2
Lyso-PAF - 12.2 f 1 .9 11 .2 t 1 .9
Lyso-PAF 100 4.2 t 1 .2 2 .1 t 1 .7
PBDB - 3.2 t 1 .5 1 .7 f 1 .9
PBDB + lyso-PAF - 12.3 t 1 .8 10.2 t 1 .9922
Both antiflammins were highly inhibitory for neutrophil chemotaxis (Fig. 5 B). In
contrast, 5 AM SRI 63072 inhibited chemotaxis only -25%. This finding indicates
that antiflammins are inhibitory for the leukotactic activity of C5a that is presum-
ably mediated by eicosanoids rather than by PAF, since it is marginally sensitive
to a PAF receptor antagonist (26).
Antiflammin-2 Inhibits the Increase in Vascular Permeability andLeukocyte Infiltration In-
duced by an Arthus Reaction, C5a or TNF. A reverse passive Arthus reaction was in-
duced in Lewis rats by intravenous injection of BSA and Evans blue followed after
30 min by intradermal injection of anti-BSA antibody (24). The rats were killed
3 h after the last injection and the area of Evans blue extravasation was first mea-
sured (Table VI). Circular skin areas were then excised and processed for light mi-
croscopy examination as describedin Materialsand Methods. We counted thePMN
presentaround vessels at thecenter of the intradermal injectionto quantitate leuko-
cyte infiltration (see Materials and Methods). The Arthus reaction was character-
ized by severe inflammatory lesions in dermis around vessels, by edema and focal
interstitial hemorrhage associated with increased vascular permeability, as judged
by the extravasation of Evans blue (Table VI). An intradermal injection of 100 ng
of AF-2 together with the anti-BSA antibody suppressed this increase in vascular
permeability and theleukocyte infiltration. The PAF receptor antagonist SRI63072
was less inhibitory than AF-2 (Table V) when injected intraperitoneally at 2.5 mg/100
g body weight (24).
In other experiments, we examined the effect of AF-2 on the increased vascular
permeability and leukocyte infiltration induced by C5a or rTNF injected intrader-
mally 30 rain after Evans blue. Injection of C5a resulted in extravasation of this
4
50-I
25
A
ANTIFLAMMINS INHIBIT PLATELET-ACTIVATING FACTOR
a
2-
B
FIGURE 5. Antiflammins inhibit neutrophils aggregation induced by C5a-des-Arg (A) and
chemotaxis induced by C5a (B). In the assayforaggregation, 0.45ml of PMNsuspension were
incubated with 50 fd of C5a-des-Arg for 2 min, as described in Materials and Methods. The
change in light transmission caused by PMN aggregation is reported as AT. PMN chemotaxis
was measured in Boyden chambers as describedin Materials and Methods and the A540 ofcells
that entered into the filterswasmeasured afterstaining with crystalviolet. The incubations con-
tained no added peptide (/), AF-1 or AF2, and the control peptide WKLFKKIEKV (*) at
theconcentrations indicated in the abscissa. The mean t SD of threeexperiments is reported.CAMUSSI ET AL.
TABLE VI
Effect ofAF-2 and the PAFAntagonist SRI 63072 (SRI) on the Increase
in Vascular Permeability and Leukocyte Infiltration Induced in Rats by an
Arthus Reaction (BSA + anti-BSA), and by C5a or TNF
Treatments, additions, and examination of skin samples are described in Materi-
als and Methods. The BSA was injected intravenously. The anti-BSA anti-
body, 50 jug of C5a, 0.2 jug of rTNF, and 0.1 Ag of AF-2 were injected
intradermally; 2.5 mg of SRI/100 gbody weight were injected intraperitoneally.
The mean t SD values obtained in three experiments are shown.
Diameter of blueing.
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dye and leukocyte infiltration (Table VI). The AF-2 inhibited this activity of C5a,
but the PAF receptor antagonist was scarcely inhibitory. Intradermal injection of
rTNF increasedvascular permeability andleukocyteinfiltration much less than other
treatments and leukocytes were mainly accumulated in the lumen of vessels as in-
travascular aggregates adherent to the endothelium. Both AF-2 and SRI 63072 in-
hibited this activity of rTNF (Table VI). These results show that AF-2 inhibits the
increase in vascular permeability and leukocytes infiltration induced by all treat-
mentstested. In contrast, the PAF receptor antagonist inhibits marginally the effect
of C5a. This finding suggests that antiflammins inhibit a response to C5a that is
not apparently mediated by PAF.
Discussion
The antiflammins are potent inhibitors of PAFsynthesis induced in macrophages
and PMN by rTNF or phagocytosis, and in endothelial cells by thrombin. These
findings suggest that antiflammins inhibitenzymatic activities required for the syn-
thesis of PAF, in agreement with the report by Miele et al. (15) that these peptides
inhibit isolated PLA2. Two features of the inhibitory activity of antiflammins were
discovered by studying their effect on PAFsynthesisin intact cells: (a)thesepeptides
inhibit PAF synthesis without a significant lag; and (b) this inhibition is reversed
by washingcellspreincubated with antiflammins. This findingshowsthat antiflammins
do not irreversibly inactivate enzymatic activities.
We measured the release of label from cells preincubated with [t4C]arachidonic
acid to estimate the PLA2 activity in PMN stimulated by rTNF or phagocytosis.
Although arachidonic acid may be released from cellular phospholipidsby the phos-
pholipase C-diacylglycerol lipase pathway, it is well documented that in PMN most
of the arachidonic acid is released by direct deacylation of phospholipids by PLA2
(27). At the present time, this is the most convenient assay for PLA2 activity in in-
tact cells. In such an assay, antiflammins are inhibitory only in the presence ofareducing
agent such as ME. This findingsuggests that antiflammins are inactivated by oxida-
Treatment - AF-2 SRI
Additions
- AF-2 SRI
MM* PMN/0.032 mm2
BSA+anti-BSA 17 1 2 2 1 1 7 1 3 46 1 12 3 1 2 11 f 4
C5a 15 1 3 4 f 1 11 t 4 26 f 8 3 1 2 21 t 3
TNF 712 0 0 1214 3t 1 211
Control 3 1 1 ND ND 3 1 1 ND ND924
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tion. However, AF-2 inhibits PAF synthesis even after a 30-min preincubation with
PMN, whereas AF-1 is not inhibitory after a 5-min preincubation (Fig. 2). This
finding shows that PMN inactivate AF-1 much faster than AF-2 . The only differ-
ences in amino acid sequence between these antiflammins are the MQ-HD substi-
tutions in residues 1-2, and the S-L substitution in residue 9. It is possible that
the NH2-terminal Met of AF-1 is oxidized by PMN secretory products. However,
this Met residue is not essential for the biological activity of antiflammins, since
it is substituted by His in AF-2 (15).
The first two residues of AF-1 can be replaced but not deleted without loss of ac-
tivity, suggesting that the length of antiflammins is critical, possibly for conforma-
tional reasons (15). Oxidation of the NH2-terminal Met may disrupt the confor-
mation ofAF-1 and account forthelower inhibitory activity of this peptide. However,
we cannot exclude that AF-1 is less inhibitory than AF-2 forotherreasons(e.g., cleavage
by a proteinase with trypsin-like specificity of the Lys-Lys peptide bond that is not
present in AF-2). Oxidation ofthe Met residue in position 3 may result in inactiva-
tion of all antiflammins, as suggested by the loss of activity after a 5-min incubation
with 1 mM H202 (our unpublished observations). This Met residue may be less
sensitive to oxidation than an NH2-terminal Met since only AF-2 remains active
in the presence of reducing agents.
Another novel finding is the inhibition of acetyl-CoA:lyso-PAF acetyltransferase
activity in cells treated with antiflammins (Fig. 4). However, antiflammins do not
inhibit this enzymatic activity in an in vitro assay with cell homogenate. This finding
cannot be explained by AF-2 inactivation, since this peptide inhibits PLA2 activity
in PMN homogenate (Table IV). A major difference between the assays for PLA2
andfor acetyltransferase maypossibly account forthe lack of inhibition ofthe latter
enzyme. PLA2 can be activated in cell-free systems whereas the acetyltransferase
can be activated only in intact cells. The activation of certain PLA2 under specific
conditions apparently involves dimerization ofthis enzyme (28-29). These findings
cannot be presently generalized and certainly cannot be extrapolated to the action
of PLA2 on phospholipids in biological membranes. However, they provide an ex-
ample ofa specific activation mechanism forPLA2. Ourfindings are consistent with
the hypothesis that antiflammins impair PAF synthesis by inhibiting the activation
of both PLA2 and acetyltransferase. Such hypothesis explains why these peptides
do notinhibit in cell-free systems theacetyltransferase alreadyactivated in intact cells.
Antiflammins inhibit neutrophil chemotaxis, and the increase in vascular perme-
ability and leukocyte infiltration induced by C5a. These inflammatory responses
are apparently not mediated by PAF since they are not significantly inhibited by
the PAF antagonist SRI 63072. This indicates that antiflammins inhibit synthesis
of other inflammatory mediators, such as leukotrienes, derived from arachidonic
acid. Leukotriene B4 is a potent chemotactic agent that mediates changes in vas-
cular permeability and may be involved in the response to C5a (30). By inhibiting
PLA2, the antiflammins block synthesis of all eicosanoid mediators produced from
arachidonic acid by specific enzymes. Therefore, antiflammins may displaya wider
antiinflammatory activity than drugs active on single enzymes, such as cyclooxygenase
or lipooxygenase inhibitors.
The antiflammins are promisingantiinflammatory agents. Ourobservations sug-
gest that these peptides may produce a striking pharmacological effect at nM con-CAMUSSI ET AL.
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centration. An intradermal injection of100ng ofAF-2 suppresses the inflammatory
response inanArthus reaction (Table VI). This suppression isobserved with a lower
antiflammindose than that used to inhibit the carrageenan-induced rat paw edema
(15). Injection of -500 kg AF-2 in the rat subplantar space inhibits 96% of the
swelling caused by carrageenan, but lower amounts are much less inhibitory (15).
These two inflammatory reactions are quite different and the effect of antiflammins
cannotbemeaningfully compared. Furthermore, inourexperimentstheantiflammins
were injected together with 10 j,M ME that may enhance their activity. In conclu-
sion, AF-2 or another peptide ofsimilar activity, but with the Met replaced by an-
otheramino acid residue to improveitsstability, are good candidates as antiinflamma-
tory agents in acute and chronic diseases.
Summary
Synthetic peptides corresponding to the region ofhighestsimilarity between human
lipocortin I and rabbit uteroglobin inhibit phospholipase A2 and show potent an-
tiinflammatory activity on the carrageenan-induced rat footpad edema (15). The
peptideHDMNKVLDL (antiflammin-2) inhibits the synthesisofplatelet-activating
factor (PAF) induced by TNF or phagocytosis in rat macrophages and human neu-
trophils, and bythrombin in vascular endothelial cells. ThepeptideMQMKKVLDS
(antiflammin-1) is less inhibitory than antiflammin-2 for macrophages and not in-
hibitory for neutrophils after a 5-min preincubation. This finding suggests that
antiflammin-1 is inactivated by neutrophils secretory products, possibly oxidizing
agents. Synthesis ofPAF is inhibited by antiflammin-2 without an appreciable lag,
but this inhibition is reversed when neutrophils or macrophages are washed and
incubated in fresh medium. Therefore, antiflammins must be continously present
to inhibit PAF synthesis. Antiflammins block activation ofthe acetyltransferase re-
quired for PAF synthesis, suggesting that this enzyme is another target for the in-
hibitory activity ofantiflammins. Thesepeptides inhibit neutrophil aggregation and
chemotaxis induced by complement component C5a. Antiflammin-2 suppressesthe
increase in vascular permeability and the leukocyte infiltration induced in rats by
an Arthus reaction or by intradermaI injection of rTNF and C5a.
We thank Dr. Anil B. Mukherjee ofthe National Institute ofChild Health and Human De-
velopment, NIH, for the gift ofpeptides, for advise and criticism, and for sharing with us
unpublished information.
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